Sinalização JAK/STAT
Os inibidores da sinalização JAK/STAT são compostos que interrompem a via da Janus quinase (JAK) e do transdutor e ativador da transcrição (STAT), que está envolvida na sinalização de citocinas, crescimento celular e resposta imunológica. Esses inibidores são ferramentas importantes para estudar a regulação dessa via e seu papel em diversas doenças, incluindo cânceres, distúrbios imunológicos e condições inflamatórias. Os inibidores de JAK/STAT também estão sendo desenvolvidos como terapias direcionadas para essas doenças. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de sinalização JAK/STAT de alta qualidade para apoiar sua pesquisa em biologia molecular, oncologia e imunologia.
Subcategorias de "Sinalização JAK/STAT"
Foram encontrados 321 produtos de "Sinalização JAK/STAT"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JAK1/TYK2-IN-3
<p>JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.</p>Cor e Forma:SolidJAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Fórmula:C23H22Cl2N4OCor e Forma:SolidPeso molecular:441.35TYK2 ligand 2
CAS:<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Fórmula:C24H20FN7O4Cor e Forma:SolidPeso molecular:489.458iBFAR2
CAS:<p>iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.</p>Fórmula:C19H15F3N2O2Cor e Forma:SolidPeso molecular:360.33JAK3 covalent inhibitor-1
CAS:<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Fórmula:C22H17FN6O2SPureza:98%Cor e Forma:SolidPeso molecular:448.47AJI-100
CAS:<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Fórmula:C17H14FN5OCor e Forma:SolidPeso molecular:323.32AJI-214
CAS:<p>AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).</p>Fórmula:C17H13ClFN5OCor e Forma:SolidPeso molecular:357.77Tyk2-IN-3
CAS:<p>Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).</p>Fórmula:C25H24N6O3S2Pureza:98%Cor e Forma:SolidPeso molecular:520.63(3S,4R)-Tofacitinib
CAS:<p>(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).</p>Fórmula:C16H20N6OPureza:98%Cor e Forma:SolidPeso molecular:312.37SI-109
CAS:<p>SI-109 is a potent inhibitor of STAT3 SH2 domain (Ki=9 nM),and with antitumor activity.</p>Fórmula:C40H44F2N7O9PPureza:98%Cor e Forma:SolidPeso molecular:835.79(R)-9b
CAS:<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Fórmula:C20H27ClN6OCor e Forma:SolidPeso molecular:402.92JAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Fórmula:C20H15ClF3N3OSCor e Forma:SolidPeso molecular:437.87JAK2-IN-11
CAS:<p>JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.</p>Fórmula:C31H31F3N8O4Cor e Forma:SolidPeso molecular:639.64PF-06263276
CAS:<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Fórmula:C31H31FN8O2Pureza:98%Cor e Forma:SolidPeso molecular:566.63lirucitinib
CAS:<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Fórmula:C16H25N5OSCor e Forma:SolidPeso molecular:335.468JAK3-IN-7
CAS:<p>JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after</p>Fórmula:C17H20N6OPureza:98.81%Cor e Forma:SolidPeso molecular:324.38LNK01004
CAS:<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Fórmula:C26H31N7O2Cor e Forma:SolidPeso molecular:473.57AZ-3
CAS:<p>AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).</p>Fórmula:C20H28FN7Pureza:98%Cor e Forma:SolidPeso molecular:385.48Milpecitinib
CAS:<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Fórmula:C20H20N4O2SCor e Forma:SolidPeso molecular:380.463Prohibitin ligand 1
<p>Compound 22i, a prohibitin ligand, protects the heart at nanomolar levels by inducing STAT3 phosphorylation.</p>Fórmula:C20H22N2OCor e Forma:SolidPeso molecular:306.4
